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Neglected Diseases
Cytomegalovirus (CMV), a member of the herpesvirus family, was a familiar cause of blindness and death in patients with advanced AIDS in Western countries 
prior to the introduction of highly active antiretroviral 
therapy (HAART). CMV retinitis then occurred in roughly 
one-third of patients with AIDS, and accounted for over 
90% of cases of HIV-related blindness [1]. Extraocular CMV 
disease was a major cause of AIDS-related morbidity and 
mortality [2]. CMV retinitis is now clinically infrequent in 
patients with AIDS in developed countries, thanks to the 
widespread availability of HAART, although the problem 
has not disappeared [3,4]. Successful fundamentals of 
management are screening eye examinations in patients 
with low CD4 counts, and effective anti-CMV treatment with 
ganciclovir and related compounds, combined with HAART.
In developing regions of the world where the HIV/AIDS 
pandemic is rapidly unfolding, CMV retinitis is a neglected 
disease, largely undiagnosed and untreated. Workable 
diagnostic and therapeutic strategies have not yet been 
defined, and CMV is absent from current and pending World 
Health Organization (WHO) guidelines for the management 
of HIV in resource-limited settings. Similarly, the WHO’s 
ambitious “Vision 2020” program, which seeks to provide 
guidance on the use of ophthalmologic resources until the 
year 2020, fails to mention CMV retinitis.
The scale of the CMV problem in developing regions is 
still not known, as most cases of CMV retinitis are never 
diagnosed. Routine retinal examination is rarely performed 
and the diagnosis may not be considered unless a patient 
has damaged vision, or even becomes irreversibly blind. 
Mortality due to extraocular CMV disease is almost impossible 
to attribute without autopsy, and so is wrongly ascribed, 
usually to “advanced HIV infection” or tuberculosis. Yet it 
has been estimated that “between 5% and 25% of all HIV-
infected patients in the developing world can be expected 
to develop this blinding disorder at some point during the 
course of their illness” [5], leading some to warn of a possible 
“epidemic of blindness” [6]. Recent direct evidence for the 
substantial scope of this neglected problem comes from a 
tertiary care ophthalmology center in Chang Mai, Thailand, 
where in a large consecutive series of referrals, 19% of the 
cases of bilateral blindness were caused by CMV retinitis, 
following only cataract as a cause of blindness, and exceeding 
glaucoma, age-related macular degeneration, and diabetic 
retinopathy [7].
In this article we provide preliminary data describing 
the problem and suggest possibilities for management of 
CMV retinitis in resource-poor settings. Our observations 
are based on the clinical experience from Médecins Sans 
Frontières (MSF) HIV/AIDS projects in Cambodia, South 
Africa, Lesotho, Myanmar, Thailand, and China, and on field 
assessments of four of these programs, and other programs 
at other locations, by the corresponding author (DH), an 
ophthalmologist with clinical training and experience with 
uveitis and CMV retinitis.
Epidemiology
In developing countries CMV infection is usually acquired 
in childhood, and nearly 100% of adults are seropositive 
[8,9,10]. Like other herpesvirus infections, CMV may remain 
latent for life. Overt clinical disease occurs with waning 
immunity.
Available data on the epidemiology of CMV retinitis in 
developing countries are difficult to interpret, as the patients 
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are often not stratified by CD4 lymphocyte counts, and both 
the technique and quality of retinal examination are variable. 
The “gold standard” for diagnosing CMV retinitis is indirect 
ophthalmoscopy with fully dilated pupils, yet some studies 
are done without dilation, and some use only the direct 
ophthalmoscope with a narrow field of view that will miss many 
cases of infection [11]. Although prevalence estimates for 
HIV infection are now generally available, the proportion of 
HIV-infected patients with advanced disease and CD4 counts 
below 50 cells/µl, the level of immunodeficiency at which 
CMV retinitis generally occurs, is often not known. As such, it 
is difficult to extrapolate the magnitude of the epidemic.
From the limited data available, it appears that the extent 
of the problem in Southeast Asia is similar to that observed 
in the pre-HAART era in Europe and the United States. 
Ophthalmology centers in Chiang Mai, Thailand, and 
Chennai, India report prevalence rates of CMV retinitis in 
patients with HIV of 33% and 17%, respectively [12,13], 
although other Southeast Asian studies have reported lower 
figures [14].
In Africa, the CMV problem appears to be less severe, 
with reported prevalence rates from cross-sectional surveys 
ranging from 0%–8.5%. [15]. However, a longitudinal study 
from Togo, which followed 200 patients for 20 months, 
found a cumulative CMV retinitis incidence of 21.4% [16]. In 
that setting, mean survival after a diagnosis of CMV retinitis 
was 22 days. The short duration from diagnosis to death 
in this example suggests that cross-sectional surveys may 
underestimate the cumulative risk of CMV.
In resource-poor settings, underdiagnosis is clearly the 
most significant problem in establishing an accurate picture 
of the epidemiology of CMV. But several issues besides 
diagnostic constraints might explain discrepancies in 
reported prevalence of CMV retinitis. Plausible explanations 
notably include regional variation in the length of survival of 
patients with low CD4 counts—short survival times reducing 
the period of risk for CMV—and different genetically 
determined host vulnerabilities to CMV [17].
Our screening studies in patients with CD4 counts below 
50 cells/µl (Table 1) show a high attack rate in Southeast 
Asia, and a lower prevalence in more limited studies from 
sub-Saharan Africa, where, nevertheless, CMV retinitis still 
represents a substantial problem due to the large absolute 
numbers of people infected with HIV. Our observations 
support the hypothesis that CMV retinitis is substantially 
underdiagnosed.
Diagnosis and Clinical Course of CMV Retinitis
The “gold standard” for diagnosis of CMV retinitis is 
examination of the retina through a dilated pupil by a skilled 
clinician using an indirect ophthalmoscope. Dilation of the 
pupil is critical, because CMV retinitis can occur anywhere 
in the retina and without a dilated pupil only a fraction of 
the retina can be examined. Retinal examination is highly 
sensitive and specific, and can be performed by any clinician 
after about one month’s training. Diagnosis of CMV retinitis 
does not require laboratory tests or eye tests [18]. Patients 
are typically easy to examine because the ocular media is 
clear and the pupil dilates well. With a skilled examiner and 
a cooperative patient with dilated pupils, the exam can be 
performed in less than two minutes.
CMV retinitis is characterized by dense retinal whitening, 
which can vary in appearance from “fluffy” to “dry and 
granular.” Hemorrhage is frequently present, but in highly 
variable amounts, and may be absent. The retinitis tends to 
follow vessels, spreading centrifugally, often in a brush-fire 
Summary Points
u In Western countries in the pre-HAART era, about 1/3 of 
patients with AIDS suffered potentially blinding CMV retinitis. 
Extraocular CMV infection in the CNS, gastrointestinal tract, 
and other organs contributed to AIDS-related mortality.
u In developing countries, CMV retinitis has been neglected, 
with little data describing the scope of the problem, and no 
strategy for management of the disease.
u Retinal screening examinations were conducted at the 
primary care level in AIDS clinics in five countries of sub-
Saharan Africa and Southeast Asia in 325 patients with CD4 
counts below 50 cells/µl. Twenty percent of patients had CMV 
retinitis, usually not previously diagnosed, and additional 
studies found 37% of individual eyes with CMV retinitis were 
blinded by the infection. 
u Successful management of CMV retinitis is a realistic goal, 
and must begin with decentralizing diagnostic capacity to 
the primary care level. All high-risk patients (at minimum all 
patients with CD4 count below 50 cells/µl) must have retinal 
screening examination with the pupil fully dilated and using 
an indirect ophthalmoscope.
u Treatment with valganciclovir, an oral medication that is 
effective for both ocular and systemic disease, is essential. 
Valganciclovir, a single-source monopoly product, is 
prohibitively expensive at present, but must be made 
available and affordable.
doi:10.1371/journal.pmed.0040334.g001
Figure 1. Example of CMV Retinitis
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fashion, with central clearing where the retina has already 
been completely destroyed; the border of active retinitis 
is irregular, and small white satellite lesions are highly 
characteristic (Figure 1).
In untreated patients with AIDS, the natural history of 
CMV retinitis is a slow but relentlessly progressive necrotizing 
retinitis with destruction of the entire retina in three to six 
months [19,20]. The zone of retinitis advances at a rate of 
approximately 750 microns, or half a “disc diameter” every 
three weeks. Based on the rate of spread, the most common 
condition confused with CMV retinitis—HIV retinopathy with 
“cotton-wool” spots—can easily be distinguished by repeat 
examination after three to four weeks. “Cotton-wool” spots 
condense or fade while CMV retinitis advances.
Blindness from CMV is permanent, and may occur 
well before full destruction of the retina. There are three 
mechanisms for vision loss, and for each mechanism early 
diagnosis is crucial to preserve vision. First, blindness may 
occur from direct damage to the macula or optic nerve. 
Second, blindness can result from retinal detachment, 
either during the acute infection or later, even years after 
the CMV retinitis has resolved. In the pre-HAART era in 
Western countries, patients with CMV retinitis developed 
retinal detachment at a rate of 33% per eye/per year [21]. In 
resource-poor settings, a patient who develops a CMV-related 
retinal detachment will be left with a permanently blind eye. 
Finally, up to 20% of patients with CMV retinitis may develop 
immune recovery uveitis (IRU) [22], after reconstitution of 
the immune system by HAART. IRU may cause vision loss 
from vitritis, retinal membrane formation, cystoid macular 
edema, or cataract. The larger the area of CMV retinitis, the 
greater the risk of both retinal detachment and IRU [23,24], 
again providing a compelling rationale for the benefit of early 
diagnosis and treatment.
Symptoms and the Need for Systematic Retinal 
Screening
CMV retinitis does not cause pain or redness in the involved 
eye. Characteristic symptoms are floaters, scotoma, photopsia, 
and blurred vision, [12,25] and although some reports 
suggest symptoms are common [25], they are frequently 
discounted or ignored. Clinical experience shows that 
limiting retinal examination only to patients with symptoms 
is not reliable, and that systematic retinal screening 
examination of vulnerable patients with or without symptoms 
is essential [26]. The efficacy of screening asymptomatic 
patients has been demonstrated [27], and meets generally 
accepted criteria for appropriate screening interventions: 
the disease is common, treatable, and easy to diagnose at 
an early stage, and the consequence of blindness is severe. 
Determination of visual acuity with an eye chart, the most 
commonly used eye screening test, measures only foveal 
function, representing less than 1% of the retinal surface, and 
is a poor test for CMV retinitis.
We believe that systematic screening examination of the 
retina should become a fundamental requirement of HIV-
related care in resource-poor settings. In our recent work 
in Myanmar, 13/42 (31%) patients diagnosed with CMV 
retinitis had no symptoms; an MSF study in Cambodia that 
used a questionnaire specifically designed to elicit symptoms 
of CMV retinitis found that almost half of the patients with 
CMV retinitis (17/39, 44%) had no symptoms at the time the 
disease was detected by screening examination [28].
Treatment
Successful treatment of CMV in patients with AIDS requires 
both specific medication against CMV and recovery of 
immune function through the use of antiretroviral therapy. 
Antiretrovirals are continued indefinitely, while specific 
treatment for CMV retinitis is continued at least until the 
retinitis resolves. Once there is some restitution of immune 
function and the CD4 count is increased to above 100 cells/µl 
(and commonly after at least three months), reactivation of 
CMV retinitis is unlikely [29,30]. Thus specific treatment of 
CMV retinitis is usually required for only a limited vulnerable 
window of time.
Ganciclovir, the traditional “gold standard” for treatment of 
CMV [31,32], can be administered systemically (daily or twice 
daily intravenous infusion), or locally (intraocular injection). 
Valganciclovir, a well-absorbed valine ester prodrug of 
ganciclovir, can achieve equivalent blood levels when given 
by mouth, and is equally effective as intravenous ganciclovir 
[33]. Other anti-CMV agents such as foscarnet and cidofovir 
are more toxic or expensive, and no more effective [34,35].
Table 1. CMV Retinitis in Patients with AIDS with CD4 Counts Below 50 Cells/µl
Location # Patients # Patients with CMV 
Retinitis
Percent of Patients Found to Have CMV 
Retinitis in Prior Reports
Siem Reap, Cambodia 74 17 (23%) 1.12 % [11]
Yangon, Myanmar 131 36 (27%) 1.9%a
Kuchinarai District Hospital (Kalasin Province) & 
Bangkwang Prison (Bangkok), Thailand
37 12 (32%) 33% [9]
Kampala, Uganda 26 2 (8%) no data 
Khayelitsha, South Africa 57 1 (2%) no data 
Total 325 68
Screening was conducted at the primary care level, in the HIV/AIDS clinic or ward, in an “open-ended” investigation to explore the value of retinal examination at the primary care level for 
patients with AIDS in resource-poor settings, with particular attention to CMV retinitis. Patients were screened for any of the following reasons: a CD4 count below 50 cells/µl, presence of 
eye symptoms, clinical stage 4 disease in the absence of biological parameters, or presence or suspicion of other opportunistic infections. 480 patients with HIV infection were screened 
(Cambodia 97, Uganda 70, South Africa 83, Myanmar 179, Thailand 51). Examinations were all conducted by the primary author (DH), using an indirect ophthalmoscope on patients with 
dilated pupils.
The above table includes only those 325 patients with a documented CD4 count below 50 cells/µl at any time. With few exceptions, the diagnosis of CMV retinitis had not yet been made.
aUnpublished MSF–Holland Yangon project data of 1,185 patients who had CD4 counts below 50 cells/µl at the start of antiretroviral treatment, with 23 diagnosed with CMV retinitis.
doi:10.1371/journal.pmed.0040334.t001
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At this time only intraocular ganciclovir injection—local 
treatment—is considered a viable option in resource-
poor settings. For both intravenous ganciclovir and oral 
valganciclovir, the primary issue is drug cost. A two-weeks 
induction treatment with intravenous ganciclovir costs 
US$1,583, and oral valganciclovir costs US$2,136. For 
maintenance treatment intravenous ganciclovir costs US$57 
each day, and oral valganciclovir costs US$76 each day, 
based on average wholesale price in the United States [36]. 
In contrast, the cost of the medication in a single weekly 
intraocular ganciclovir injection is only US$0.57. But these 
figures are misleading because they ignore the cost of surgical 
supplies (often not available), and do not put a dollar amount 
on physician time and skills.
Intraocular injection of ganciclovir is certainly preferable to 
no treatment, even though it fails to address systemic disease. 
This treatment is highly effective for local disease. It should 
be made widely available as an alternative therapy, and may 
prove particularly useful in four situations: (1) patients with 
pre-existing cytopenia, since bone marrow suppression is a 
known side effect of ganciclovir; (2) patients who are poorly 
compliant with oral treatment; (3) patients unable to swallow 
pills or with poor gastrointestinal absorption; and (4) patients 
who have clinically failed to respond to oral medication. 
Initiating treatment with intraocular injection (for two weeks) 
in addition to oral valganciclovir may also be considered for 
“induction,” in order to most rapidly gain control of infection 
in patients when the disease is near the optic nerve or macula 
and is thus immediately sight-threatening.
Unfortunately, the availability of intraocular ganciclovir 
treatment in resource-poor settings has been extremely 
limited, and this situation will probably continue. Clinicians 
trained in intraocular injection are in short supply, and 
local regulations, such as in Thailand, may restrict this 
treatment to ophthalmologists. Also, intraocular injection is 
an invasive treatment with a low rate of serious complications 
(endophthalmitis, vitreous hemorrhage, retinal detachment, 
and cataract) [37,38]. Patient acceptance is another barrier 
and intraocular injection can be frightening to patients. 
Compliance may be especially difficult in patients who 
would benefit most—those with minor or no symptoms. 
As the capacity for diagnosis of CMV retinitis develops, a 
higher volume of services will be required, including the 
presentation of more patients with asymptomatic disease. The 
intraocular injection strategy will grow still less satisfactory. 
Providing a simple pill is far more realistic.
We believe that systemic treatment with oral valganciclovir 
should be used routinely as the primary treatment strategy 
because (1) systemic treatment of CMV retinitis reduces 
extraocular CMV disease [39]; (2) systemic treatment reduces 
mortality [40,41]; and (3) with only local treatment there is 
a 22%–35% incidence of new CMV retinitis in the untreated 
contralateral eye [37,38]. Intraocular ganciclovir as the 
primary treatment strategy is simply not medically adequate.
Valganciclovir is an essential drug for the treatment of 
CMV retinitis. Without this option most patients with CMV 
retinitis will never be treated.
Consequences of Neglecting CMV Retinitis
We have unequivocally observed that CMV retinitis is causing 
blindness in a young population in developing countries 
(Table 2), even though the full scope of the problem remains 
to be defined.
The vision loss from CMV is commonly profound or total 
(Table 3), and permanent, which means that the patient will 
require near constant assistance from another individual and 
retain little or no capacity for independent existence. The 
stark reality is that conditions favorable to the development of 
CMV retinitis—patients with low CD4 counts in the absence 
of HAART—are most common in impoverished rural areas 
where profound blindness will have a devastating impact on 
the entire family, and often a fatal outcome for the patient. 
For the cohort of blind patients that survive, there looms the 
social, economic, and indirect personal health consequences 
Box 1. Introducing a CMV Retinitis Diagnosis and 
Treatment Strategy in Thailand
Thailand is one of few developing countries to provide HAART 
nationwide [55], treatment being available at 800 hospitals [56] 
and some health centers [57]. The national protocol for CMV 
retinitis diagnosis and treatment includes screening of patients 
with CD4 count below 100 cells/µl, induction therapy with 
intravenous ganciclovir, and maintenance therapy with either 
intravenous or intraocular ganciclovir [58]. In practice, however, 
diagnostic capacity only exists in specialist centers, and there is 
no allocation in the national budget for this disease, although it 
is planned for 2008.
In Kuchinarai District, Northeastern Thailand—the country’s 
poorest region—200 people with HIV receive HAART through 
the district hospital in a project supported by MSF since 2002. 
Most patients first present with advanced disease, 17% having 
been diagnosed with CMV retinitis following visual symptoms. 
Regular screening by indirect ophthalmoscopy is being 
introduced, performed by two general medical practitioners 
following initial training at a tertiary referral hospital. Their initial 
training (one week only) could not provide complete skills, but 
was sufficient to create a referral system whereby patients with 
suspected CMV retinitis are referred to the tertiary center for 
confirmation of diagnosis and intraocular ganciclovir injection.
However, many patients live up to 25 km from the hospital 
and public transport in this district is lacking. For earlier 
diagnosis, we are introducing screening where the first patient 
contact often occurs—at the health station level. Screening is 
done by the hospital’s general practitioners during monthly 
visits. Clinical management of CMV retinitis needs to be 
integrated into HIV care at both the district hospital and health 
station level, and availability of systemic treatment of CMV 
retinitis with oral valganciclovir would make this far more 
feasible.
Valganciclovir is available from Roche for transplant 
patients in Thailand, but the cost for treating CMV would be 
$US9,398 (Assumptions for price calculation: Induction phase 
of 900 mg twice daily for 21 days, followed by maintenance 
phase of 900 mg once daily for three months. A three month 
supply of a comparable off-patent product such as acyclovir 
is available for $US89 on the international market (median 
price). In negotiations with MSF’s Access to Essential Medicines 
Campaign, Roche has offered $US1,800 for use in AIDS patients 
by nongovernmental organizations in sub-Saharan African 
countries and least developed countries. However, Thailand was 
excluded from this offer.
(David Wilson and A. Kace Keiluhu)
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of permanent profound blindness at a young age, coupled 
with HIV infection, a now treatable chronic disease.
Failure to diagnose CMV retinitis, and failure to treat 
affected patients with systemic anti-CMV medication, has an 
unfavorable impact on AIDS-related morbidity and mortality, 
because CMV is a systemic disease [42], and the extraocular 
forms of CMV, including colitis, esophagitis, encephalitis, 
radiculitis, pneumonitis, bone marrow suppression, and 
disseminated CMV infection, can be life-threatening. In the 
West, in the pre-HAART era, CMV infection was found at 
autopsy in over half of patients with AIDS [43,44,45], and 
CMV disease of the central nervous system (CNS) was found 
in about 10% of autopsy patients [46,47,48]. 
At least in patients with unexplained CNS disease, 
detection or exclusion of CMV retinitis has clear clinical 
diagnostic value: CNS disease in a patient with CMV retinitis 
is probably also due to CMV, while in patients free of retinitis, 
CNS symptoms are probably not from CMV infection [49,50]. 
Published studies report extraocular CMV disease as the 
primary cause of death in 1%–19% of patients with AIDS 
[2,43,51], and reduction in mortality has been observed with 
systemic treatment of CMV retinitis [40], even in patients 
failing HAART therapy [41].
Our experience in resource-poor settings is consistent with 
previous reports of morbidity and mortality from extraocular 
CMV disease. Between November 2001 and September 2006, 
MSF initiated antiretroviral therapy in 330 adult patients 
in two rural district hospitals in Northeast Thailand (Ban 
Laem District Hospital and Kuchinarai District Hospital), 
and 28 patients with visual symptoms were diagnosed 
with CMV retinitis (eye screening exams were not done). 
Six of the 28 patients with CMV retinitis also had disease 
clinically suggestive of extraocular CMV (one with ascending 
polyradiculopathy, two with encephalitis, two with esophagitis, 
and one with colitis). Four of these patients died.
Finally, experience in Cambodia, Thailand, and Myanmar 
shows that, at least in Southeast Asia, in the first several years, 
programs that offer HAART in resource-poor settings attract 
large numbers of patients with advanced disease and low 
CD4 counts—exactly those most vulnerable to CMV retinitis. 
CMV management becomes a pressing issue with the scale-
up of HAART, and failure to address the problem of CMV 
retinitis will have negative consequences for the management 
of HIV/AIDS programs. Blindness is extremely distressing 
for the patient and family and also causes loss of faith in 
HIV treatment amongst health staff. In cases where loss of 
sight occurs without explanation after institution of HAART, 
patients may begin to associate HAART with blindness, and 
in the worst case scenario this may lead to reluctance to start 
taking this life-saving therapy.
What Can Be Done?
Treatment of opportunistic infections is an integral part of 
HIV management at the primary care level, and treatment of 
CMV retinitis should be included. Patients with CMV retinitis 
are often too sick or lack adequate financial or social support 
to reach specialists [52]. In most places in the developing 
world there are too few ophthalmologists to manage the CMV 
problem, and like other specialists, they are concentrated 
in major cities, relatively inaccessible to rural locations and 
to the poor [53]. Ophthalmologists are often not highly 
motivated to care for patients with AIDS, and have other 
priorities, including a growing backlog of 45 million patients 
waiting for sight-restoring cataract surgery globally [54].
Two steps are critical:
1. Diagnostic capacity must be expanded and decentralized 
to the primary care level. HIV/AIDS programs that offer 
HAART should designate a clinician to be trained in retinal 
examination with the indirect ophthalmoscope. A sturdy 
portable indirect ophthalmoscope (Scan Optics, US$1050 
complete with 28D lens; http://www.scanoptics.com.au/) is 
available, and has been field-tested in rural South Africa by an 
MSF HIV clinician who received a one-month pilot training 
course at the Aravind Eye Institute in India. This could be 
the first step in development of a simple training package 
for diagnosis and treatment of CMV retinitis at the primary 
care level, with identification and development of regional 
centers where training can take place. A similar step is being 
facilitated by MSF in Thailand (see Box 1).
2. Valganciclovir must be made available and affordable.
Many HIV/AIDS programs in resource-poor settings are 
hesitant about investing resources to develop diagnostic 
capacity because treatment is unavailable or unaffordable. 
Making valganciclovir pills available for the treatment of CMV 
retinitis will provide powerful encouragement for HAART 
programs to address the problem of CMV.
Conclusions
The realistic place for managing CMV infection, like other 
opportunistic infections, is in the AIDS clinic by the AIDS 
doctors. Diagnosis and management of CMV infection should 
become part of routine care. Screening for CMV retinitis 
Table 2. Blindness among 78 Patients with CMV Retinitis from 
Cambodia, Uganda, South Africa, Thailand, and Myanmar
Condition # Patients
CVM retinitis 78
     Bilateral retinitis 25
     Unilateral retinitis 53
Bilateral blindness due to CMV 5
Unilateral blindness due to CMV 27
This table includes the 68 patients listed in Table 1, plus ten additional patients with 
CMV retinitis from the same primary care screening who did not have documented CD4 
count under 50 cells/µl (includes 5 patients with CD4 count 50–100 and 5 patients with 
eye symptoms or suspicion of other WHO stage 4 disease, but with unknown CD4 count). 
Blindness was defined according to WHO criteria of less than 3/60 visual acuity. Average 
age of the patients was 37 years.
doi:10.1371/journal.pmed.0040334.t002
Table 3. Severity of Vision Loss in 37 Eyes (of 32 Patients) 
“Blinded” by CMV Retinitis
Degree of Severity # Eyes 
Affected
No light perception 15
Light perception only 14
Can detect hand motion only 4
Bare count fingers 2
Can count fingers at less than 10 feet 2
103 eyes of 78 patients had CMV retinitis. Out of the103 eyes infected with CMV, 37 (36%) 
met WHO criteria for “blindness.”
doi:10.1371/journal.pmed.0040334.t003
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should be part of the initial evaluation of high-risk patients 
(at minimum all patients with CD4 counts below 50 cells/µl, 
and possibly other groups) when they first enter HIV care. 
The screening technique should be the same as in Western 
countries: study of the entire retina through a fully dilated 
pupil using an indirect ophthalmoscope.
Systemic treatment of CMV retinitis with oral valganciclovir 
should be standard care, just as it is in Western countries. 
Treatment with ganciclovir intraocular injection is easily 
affordable, but lack of trained clinicians skilled and available 
to perform intraocular injection restricts its use. We should 
aggressively move forward with training in essential skills and 
providing access to essential medicines.
Simple and effective management of CMV disease in 
resource-poor settings is a realistic goal, and one that 
has been overlooked in the scale-up of HIV treatment 
worldwide. Ongoing CMV-related mortality should no longer 
go unrecognized or be accepted as part of advanced HIV 
mortality. Patients should not be left vulnerable to blindness 
while clinicians are in the process of treating and controlling 
the underlying infection with HIV.
Supporting Information
Alternative Language Summary S1.
Thai Translation of the Summary by C. Klangburi and S. Kogram
Found at doi:10.1371/journal.pmed.0040334.sd001 (71 KB PDF)
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